Status:
ACTIVE_NOT_RECRUITING
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis
Lead Sponsor:
Shanghai East Hospital
Collaborating Sponsors:
National Natural Science Foundation of China
Conditions:
Non-alcoholic Fatty Liver Disease (NAFLD)
Eligibility:
All Genders
18-65 years
Brief Summary
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH). NASH is pathologicall...
Detailed Description
I. Study Background Non-alcoholic fatty liver disease (NAFLD) has become one of the most prevalent liver disorders globally. Despite its high incidence and severity, no effective therapeutic agents cu...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Non-Alcoholic Fatty Liver Disease
- Age 18-65 years
Exclusion
- Cirrhosis (compensated or decompensated)
- Hepatocellular carcinoma
- Active viral hepatitis (HBV, HCV)
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Recent history of illicit drug use
- Alcohol intake≥20 g/day for women and ≥30 g/day for men
- Current pregnancy or breastfeeding
- Severe comorbidities.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06913699
Start Date
April 1 2024
End Date
May 31 2026
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai East Hospital (East Hospital Affiliated To Tongji University)
Shanghai, Shanghai Municipality, China, 200120